189 related articles for article (PubMed ID: 36374568)
1.
Wagner J; Bell AS; Lohoff FW
ACS Chem Neurosci; 2022 Dec; 13(23):3210-3212. PubMed ID: 36374568
[TBL] [Abstract][Full Text] [Related]
2. In Vivo Base Editing of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) as a Therapeutic Alternative to Genome Editing.
Chadwick AC; Wang X; Musunuru K
Arterioscler Thromb Vasc Biol; 2017 Sep; 37(9):1741-1747. PubMed ID: 28751571
[TBL] [Abstract][Full Text] [Related]
3. New Approaches for Targeting PCSK9: Small-Interfering Ribonucleic Acid and Genome Editing.
Oostveen RF; Khera AV; Kathiresan S; Stroes ESG; Fitzgerald K; Harms MJ; Oakes BL; Kastelein JJP
Arterioscler Thromb Vasc Biol; 2023 Jul; 43(7):1081-1092. PubMed ID: 37259866
[TBL] [Abstract][Full Text] [Related]
4. Permanent alteration of PCSK9 with in vivo CRISPR-Cas9 genome editing.
Ding Q; Strong A; Patel KM; Ng SL; Gosis BS; Regan SN; Cowan CA; Rader DJ; Musunuru K
Circ Res; 2014 Aug; 115(5):488-92. PubMed ID: 24916110
[TBL] [Abstract][Full Text] [Related]
5. Gene Editing for the Treatment of Hypercholesterolemia.
Hoekstra M; Van Eck M
Curr Atheroscler Rep; 2024 May; 26(5):139-146. PubMed ID: 38498115
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and Safety of an Investigational Single-Course CRISPR Base-Editing Therapy Targeting
Lee RG; Mazzola AM; Braun MC; Platt C; Vafai SB; Kathiresan S; Rohde E; Bellinger AM; Khera AV
Circulation; 2023 Jan; 147(3):242-253. PubMed ID: 36314243
[TBL] [Abstract][Full Text] [Related]
7. Extracellular vesicle-mediated delivery of CRISPR/Cas9 ribonucleoprotein complex targeting proprotein convertase subtilisin-kexin type 9 (Pcsk9) in primary mouse hepatocytes.
Ilahibaks NF; Kluiver TA; de Jong OG; de Jager SCA; Schiffelers RM; Vader P; Peng WC; Lei Z; Sluijter JPG
J Extracell Vesicles; 2024 Jan; 13(1):e12389. PubMed ID: 38191764
[TBL] [Abstract][Full Text] [Related]
8. Treatment of Dyslipidemia Using CRISPR/Cas9 Genome Editing.
Chadwick AC; Musunuru K
Curr Atheroscler Rep; 2017 Jul; 19(7):32. PubMed ID: 28550381
[TBL] [Abstract][Full Text] [Related]
9. Is It Ever Wise to Edit Wild-Type Alleles? Engineered CRISPR Alleles Versus Millions of Years of Human Evolution.
Kozan DW; Farber SA
Arterioscler Thromb Vasc Biol; 2024 Feb; 44(2):328-333. PubMed ID: 38059350
[TBL] [Abstract][Full Text] [Related]
10. CRISPR-Cas9 Targeting of PCSK9 in Human Hepatocytes In Vivo-Brief Report.
Wang X; Raghavan A; Chen T; Qiao L; Zhang Y; Ding Q; Musunuru K
Arterioscler Thromb Vasc Biol; 2016 May; 36(5):783-6. PubMed ID: 26941020
[TBL] [Abstract][Full Text] [Related]
11. In vivo genome and base editing of a human PCSK9 knock-in hypercholesterolemic mouse model.
Carreras A; Pane LS; Nitsch R; Madeyski-Bengtson K; Porritt M; Akcakaya P; Taheri-Ghahfarokhi A; Ericson E; Bjursell M; Perez-Alcazar M; Seeliger F; Althage M; Knöll R; Hicks R; Mayr LM; Perkins R; Lindén D; Borén J; Bohlooly-Y M; Maresca M
BMC Biol; 2019 Jan; 17(1):4. PubMed ID: 30646909
[TBL] [Abstract][Full Text] [Related]
12. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors: Present perspectives and future horizons.
Yadav K; Sharma M; Ferdinand KC
Nutr Metab Cardiovasc Dis; 2016 Oct; 26(10):853-62. PubMed ID: 27352986
[TBL] [Abstract][Full Text] [Related]
13. Proprotein convertase subtilisin/kexin type 9 (PCSK9) in lipid metabolism, atherosclerosis and ischemic stroke.
Zhang L; Song K; Zhu M; Shi J; Zhang H; Xu L; Chen Y
Int J Neurosci; 2016 Aug; 126(8):675-80. PubMed ID: 26040332
[TBL] [Abstract][Full Text] [Related]
14. Non-antibody Approaches to Proprotein Convertase Subtilisin Kexin 9 Inhibition: siRNA, Antisense Oligonucleotides, Adnectins, Vaccination, and New Attempts at Small-Molecule Inhibitors Based on New Discoveries.
Nishikido T; Ray KK
Front Cardiovasc Med; 2018; 5():199. PubMed ID: 30761308
[TBL] [Abstract][Full Text] [Related]
15. CES1-Triggered Liver-Specific Cargo Release of CRISPR/Cas9 Elements by Cationic Triadic Copolymeric Nanoparticles Targeting Gene Editing of PCSK9 for Hyperlipidemia Amelioration.
Zhao Y; Li Y; Wang F; Gan X; Zheng T; Chen M; Wei L; Chen J; Yu C
Adv Sci (Weinh); 2023 Jul; 10(19):e2300502. PubMed ID: 37083231
[TBL] [Abstract][Full Text] [Related]
16. Cyclase-associated protein 1 is a binding partner of proprotein convertase subtilisin/kexin type-9 and is required for the degradation of low-density lipoprotein receptors by proprotein convertase subtilisin/kexin type-9.
Jang HD; Lee SE; Yang J; Lee HC; Shin D; Lee H; Lee J; Jin S; Kim S; Lee SJ; You J; Park HW; Nam KY; Lee SH; Park SW; Kim JS; Kim SY; Kwon YW; Kwak SH; Yang HM; Kim HS
Eur Heart J; 2020 Jan; 41(2):239-252. PubMed ID: 31419281
[TBL] [Abstract][Full Text] [Related]
17. In vivo adenine base editing of PCSK9 in macaques reduces LDL cholesterol levels.
Rothgangl T; Dennis MK; Lin PJC; Oka R; Witzigmann D; Villiger L; Qi W; Hruzova M; Kissling L; Lenggenhager D; Borrelli C; Egli S; Frey N; Bakker N; Walker JA; Kadina AP; Victorov DV; Pacesa M; Kreutzer S; Kontarakis Z; Moor A; Jinek M; Weissman D; Stoffel M; van Boxtel R; Holden K; Pardi N; Thöny B; Häberle J; Tam YK; Semple SC; Schwank G
Nat Biotechnol; 2021 Aug; 39(8):949-957. PubMed ID: 34012094
[TBL] [Abstract][Full Text] [Related]
18. Programmable Genome-Editing Technologies as Single-Course Therapeutics for Atherosclerotic Cardiovascular Disease.
Jindal I; Wang X
Curr Atheroscler Rep; 2022 Nov; 24(11):861-866. PubMed ID: 35994136
[TBL] [Abstract][Full Text] [Related]
19. Targeting the proprotein convertase subtilisin/kexin type 9 for the treatment of dyslipidemia and atherosclerosis.
Urban D; Pöss J; Böhm M; Laufs U
J Am Coll Cardiol; 2013 Oct; 62(16):1401-8. PubMed ID: 23973703
[TBL] [Abstract][Full Text] [Related]
20. Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibition and the Future of Lipid Lowering Therapy.
Joseph L; Robinson JG
Prog Cardiovasc Dis; 2015; 58(1):19-31. PubMed ID: 25936907
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
